Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YSQ
|
|||
| Former ID |
DIB002233
|
|||
| Drug Name |
SAR-405838
|
|||
| Synonyms |
AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Ascenta Therapeutics; Sanofi US
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H34Cl2FN3O3
|
|||
| Canonical SMILES |
CC(C)(C)CC1C2(C(C(N1)C(=O)NC3CCC(CC3)O)C4=C(C(=CC=C4)Cl)F)C5=C(C=C(C=C5)Cl)NC2=O
|
|||
| InChI |
1S/C29H34Cl2FN3O3/c1-28(2,3)14-22-29(19-12-7-15(30)13-21(19)34-27(29)38)23(18-5-4-6-20(31)24(18)32)25(35-22)26(37)33-16-8-10-17(36)11-9-16/h4-7,12-13,16-17,22-23,25,35-36H,8-11,14H2,1-3H3,(H,33,37)(H,34,38)/t16?,17?,22-,23-,25+,29+/m0/s1
|
|||
| InChIKey |
IDKAKZRYYDCJDU-AEPXTFJPSA-N
|
|||
| CAS Number |
CAS 1303607-60-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036509) | |||
| REF 2 | SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. | |||
| REF 3 | SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.Clin Cancer Res.2016 Mar 1;22(5):1150-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.